In a recent study conducted by CREATION.co to determine the Top 50 Digital Opinion Leaders in type 2 diabetes (T2D) we gathered more than 320,000 English and Spanish language T2D social media posts globally. These were posted by more than 50,000 eHCPs between January 2022 and March 2023.
eHCP conversation was detected in more than 170 countries, with the most mentions coming from the United States, United Kingdom, Spain, India and Mexico. Around 18% of the overall posts around T2D were coming from the United States alone. When combined with posts from the UK, those two countries accounted for almost a third of the total posts.
On social media there are no country borders; eHCPs were seen freely communicating with their peers all around the globe and collaborating in real time through social media on a daily basis.
Comparing English and Spanish language conversations, while English was the most dominant language used by eHCPs in the study, 20% of posts were written in Spanish. CREATION.co identified conversation clusters between countries which speak the same language. For example, a number of the DOLs located in Spain had a greater level of influence into Latin America than DOLs in English speaking countries. This worked two ways as the posts from a DOL in Latin America were frequently engaged with by eHCPs in Spain.
Inteligencia Artificial (IA) en el cuidado de la diabetes. https://t.co/U7XSY6zUwf
— RAFAEL BRA (@rafael52987) November 14, 2022
Reviewing the themes in conversation from the top five posting countries certain trends and similarities were observed. In the US, the most frequently discussed topic was the treatment of T2D as eHCPs were particularly active talking about specific treatments for type two diabetes.
In the UK the volume of posts around treatment and the volume of posts around research were almost identical. eHCPs shared studies and clinical trial results, which linked T2D to other health issues and provided further insights into tackling the condition.
All medicines have potential side effects. It’s about risk v benefits. This is why it’s important to speak with your doctor about your healthcare plan and what’s best for you. #ozempic #diabetes #obesity pic.twitter.com/PptDBtNZvp
— Dr Janette Nesheiwat (@DoctorJanette) March 21, 2023
With recent update of @NICEComms as regards #T2Diabetes – plenty of queries regards use of SGLT2I
Thank you to @claireyrivs from @NHSEngland @NHSDiabetesProg for this wonderful easy to use guide
Please use, cascade, RT as you need
Thank you cc @PrimaryCareNHS @pcdsociety pic.twitter.com/R9ysQxx2lJ
— Partha S Kar 🇮🇳🇬🇧🏏🎥 (@parthaskar) June 13, 2022
In Spain, eHCPs focused on discussing treatment options with their peers, sharing their opinions and experiences on certain medications. In India treatment options were also a large part of the conversation but eHCPs also regularly discussed patient lifestyle choices to be adhered to or avoided.
If you want to find out more about our T2D study please watch the webinar: The Top 50 Global Digital Opinion Leaders in T2D or contact CREATION.co.
